A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders. It also develops iTOL-102, NCEL-201, NCEL-301, and NCEL-007. NewcelX Ltd. was founded in 2008 and is headquartered in Kloten, Switzerland.
Financial Summary
| Share Statistics | NCEL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $15.2 | $217.7 | 9% |
|
| Shares Out (Mil) | 5.9 | 53.7 | 16% |
|
| Institutional Ownership | 0.9% | 92.9% | 2% |
|
| Float (Mil) | 2.7 | 41.4 | 7% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 7 | 583 | 15% |
|
| Price Change (52-week) |
na | 45.5% | na |
|
| Growth | NCEL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (4.1%) | (10.1%) | 35% |
|
| EPS (5yr) | 14.0% | 15.7% | 54 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (35.7%) | (15.7%) | 15% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | NCEL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | $0 | ($44) | 39% |
|
| EPS (TTM) | ($0.509) | ($1.600) | 27% |
|
| Operating Cash Flow (TTM) (Mil) | ($5) | ($33) | 25% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $17 | $175 | 10% |
|
| Valuation | NCEL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.35 | 2.11 | 60% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | NCEL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.5% | na |
|
| Net Margin | na | (74.8%) | na |
|
| ROA | 1.1% | (47.1%) | 47% |
|
| ROE | (1.2%) | (54.1%) | 34% |
|
| Liabilities to Assets | 37.7% | 29.0% | 29% |
|
| F-Score | 3 | 2 | 18% |
|
NewcelX Ltd. did not pass any screens on 10/19/2026.
